The European Medicines Agency (EMA) has accepted for review an application for an add-on maintenance treatment in certain adults and adolescents (12 years and older) with inadequately controlled moderate-to-severe asthma, Dupixent (dupilumab).Read more

The US Food and Drug Administration (FDA) has accepted the supplemental biologics licence application (sBLA) of Dupixent (dupilumab) for review, revealed joint developers of the drug, Regeneron and Sanofi.Read more

The European Commission (EC) has granted marketing authorisation to Sanofi and Regeneron Pharmaceuticals for dupilumab (Dupixent) for the treatment of adults with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy.Read more

Sanofi and Regeneron Pharmaceuticals have announced that the US FDA has approved Dupixent (dupilumab) injection, which is the first targeted biologic therapy for adults suffering from moderate-to-severe atopic dermatitis.Read more

Join the EPM Community for FREE today!

EPM Magazine is the essential information source for professionals involved in the formulation, development, manufacturing and supply of drugs and medicines in the pharmaceutical and biopharmaceutical industry.